Orlistat capsules and Wegovy tablets are both oral treatments discussed in weight management, yet their drug actions and administration requirements are fundamentally different. Orlistat limits absorption of some dietary fat by inhibiting gastrointestinal lipases. Wegovy tablets contain semaglutide, a GLP-1 receptor agonist with U.S. prescription weight-management labeling for eligible adults. Calling both products “weight-loss pills” is therefore a starting description, not a reason to treat them as substitutes.
The routines illustrate the difference. Orlistat is associated with main meals containing fat, and OTC Alli 60 mg has a different U.S. access status from prescription 120 mg products. Wegovy tablets are prescription-only and have strict morning fasting instructions with a specified amount of water and a waiting period before food, drinks or other oral medicines. A person should not copy the administration approach of one medicine onto the other. This page focuses on the oral Wegovy formulation rather than the injectable Wegovy product.
Comparison also requires caution about study designs and medical history. Wegovy tablet evidence cannot be compared with orlistat trial averages as though the two had been tested head-to-head in the same trial unless such evidence is actually available. OrliLab is an informational site supported in part by disclosed affiliates, not a pharmacy or prescriber. More general Wegovy product context belongs to orlistat versus Wegovy; a wider oral class overview appears at orlistat versus oral GLP-1 medicines.
A tablet and a capsule may sound similarly convenient, but this choice involves different conditions for use, warnings and prescription pathways. The table keeps brand and formulation identity visible rather than generalizing from all semaglutide products.
The exact label should be reviewed before any clinical decision. Wegovy injection and tablets are distinct formulations, and OTC orlistat is not equivalent to prescription orlistat simply because the active ingredient is shared.
| Feature | Orlistat capsules | Wegovy tablets |
|---|---|---|
| Active ingredient | Orlistat | Semaglutide |
| Drug class | Gastrointestinal lipase inhibitor | GLP-1 receptor agonist |
| US access | Alli 60 mg OTC; 120 mg Rx | Prescription-only |
| Food routine | Taken according to meal-linked product label | Morning empty stomach with water; waiting interval |
| Characteristic GI effects | Oily stool, gas with discharge, urgency | Nausea, vomiting, diarrhea, constipation |
| Distinct risks | Vitamin absorption, interactions, kidney warnings | GLP-1 boxed warning and other product-specific precautions |
U.S. Wegovy tablets come in 1.5, 4, 9 and 25 mg strengths, with 25 mg as the labeled adult maintenance tablet strength. They are taken once daily on an empty stomach in the morning with up to four ounces of plain water. The label instructs waiting at least 30 minutes before consuming food, other drinks or other oral medicines. Tablets should be swallowed whole rather than chewed or divided. These rules are part of this oral semaglutide formulation’s approved directions.
They should not be adapted to other oral GLP-1 medicines. If a person cannot consistently fit the fasting and waiting window into a medication schedule, the prescriber should know; changing the routine can affect how the drug is taken. The Wegovy pill access guide discusses the prescription purchasing pathway, not substitute dosing advice.
Orlistat works in the gut in relation to dietary fat. Labels discuss use with the relevant main meals and what to do when a meal is missed or contains no fat. Higher-fat meals can increase the likelihood of unpleasant oily bowel effects, a practical contrast to Wegovy tablets’ fasting requirement.
That does not mean users should increase or decrease doses to match a meal or copy general internet diet rules. The details of food fat and expectations belong to orlistat and meal composition.
Wegovy tablets have U.S. labeling both for long-term weight reduction in eligible adults and for lowering the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Orlistat products also have weight-related indications, but the population criteria, prescription boundaries and supporting studies differ. Wegovy injection has additional formulation-specific uses, including some pediatric weight-management settings and an accelerated-approval indication for certain adults with MASH; those uses should not automatically be attributed to the tablet.
Read the marketed formulation rather than an ingredient-only headline. A person with diabetes, other medical conditions or concurrent medications may require additional assessment; label differences matter more than marketing descriptions such as “oral alternative.”
Published weight-management trials vary by duration, dose escalation, participant characteristics and outcomes. A Wegovy tablet trial and an orlistat study can each provide useful evidence without establishing a direct comparative effect size. Even percentage weight reductions measured at similar calendar points may reflect different populations and analysis methods.
This page therefore does not assert one treatment is more effective for an individual or manufacture a direct comparison. Orlistat effectiveness evidence belongs in its own evidence guide, while semaglutide formulation data should be read from its individual label and trials.
Orlistat is associated with oily spotting, bowel urgency, stool changes and decreased absorption of fat-soluble vitamins. More serious precautions include drug interactions, liver symptoms and oxalate-related kidney injury. The FDA’s June 2026 communication updated OTC Alli warnings about rare kidney stones and kidney injury.
A person with a history of kidney stones or disease should follow the current warnings and consult a health professional before OTC use. Orlistat kidney risk contains the dedicated discussion; this comparison remains limited to the treatment choice.
Wegovy carries a boxed warning concerning thyroid C-cell tumors observed in rodents and is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2. Its label also warns about pancreatitis, gallbladder events, serious gastrointestinal reactions and dehydration-related kidney problems, among other issues.
These risks require evaluation independent of a patient’s history with orlistat. Wegovy also delays gastric emptying, which can affect the absorption or timing of other oral medicines; a pharmacist should review the complete medication list. Seeing gastrointestinal side effects in both medicines does not imply identical contraindications or monitoring.
Alli 60 mg is available without a prescription only within its labeled conditions; orlistat 120 mg and Wegovy tablets require prescriptions. A legitimate Wegovy prescription follows a clinician’s assessment, with individual follow-up and counseling determined by the treatment plan.
No legitimate online seller can guarantee Wegovy approval or dispense it based only on an advertising quiz. For the orlistat side see orlistat purchasing options and confirm the pharmacy and product independently.
A price comparison should identify the exact orlistat strength, OTC package or prescription quantity, and the Wegovy tablet prescription plan. Coverage, medical visits, pharmacy fees, follow-up and product availability can change the total cost. No static affiliate listing establishes current stock or insurer payment.
The orlistat price guide covers evergreen product costs. Wegovy purchasing information should be verified against current licensed pharmacy and insurance information rather than assumed from advertised discounts.
Foundayo contains orforglipron, not semaglutide, and its U.S. label permits use with or without food. Wegovy tablets have a morning fasting routine. It would be inaccurate to generalize either drug’s instructions to all oral GLP-1 agents.
Readers interested in a specific Foundayo comparison can use orlistat versus Foundayo. This page remains the focused orlistat-versus-Wegovy-tablet assessment.
Clarify whether the comparison involves OTC Alli, prescription orlistat 120 mg or semaglutide tablets. Ask whether the approved indication fits the clinical goal, what daily administration requires, which warnings apply and how treatment would be monitored. A prescription-only drug should not be chosen on tablet convenience alone.
If the question is no longer pill-specific, the broader Wegovy comparison is a more appropriate guide. Individual medical decisions require professional review rather than a page-level verdict.
Yes. Wegovy tablets are FDA-approved for eligible adults, with strengths of 1.5, 4, 9 and 25 mg. The oral product has its own instructions and should not be confused with Wegovy injection.
No. Wegovy tablets require a valid prescription.
No. Orlistat inhibits digestive lipases; Wegovy tablets contain semaglutide, a GLP-1 receptor agonist.
Yes. The U.S. label directs morning use on an empty stomach with up to four ounces of plain water. Wait at least 30 minutes before food, other drinks or additional oral medicines.
No. Wegovy tablets contain semaglutide and require morning fasting instructions. Foundayo contains orforglipron and permits administration with or without food, according to its own labeling.
No. Alli 60 mg is OTC under its label, while orlistat 120 mg is prescription-only.
No. Separate trials differ in design and populations; treatment selection also depends on indications and risks.
Yes. Orlistat commonly causes fatty stools, oily spotting and urgency, whereas Wegovy may cause nausea, vomiting, constipation or diarrhea. Different symptoms do not mean the medicines have equivalent contraindications.
No. Combining or changing treatment requires evaluation of the individual plan, medicine interactions and clinical risks.
The exact formulation, labeled indication, administration rules, contraindications, medication list, cost and follow-up needs.